Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Price Target at $110.91

Posted by Brenda Bartman on Sep 8th, 2026

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $110.9091.

Several equities research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a research note on Friday, August 7th. Citizens Jmp dropped their price target on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a report on Friday, August 7th. HC Wainwright reduced their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Finally, Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th.

Get Our Latest Analysis on Structure Therapeutics

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors have recently modified their holdings of the business. Sterling Capital Management LLC bought a new position in Structure Therapeutics during the first quarter worth about $28,000. State of Wyoming bought a new stake in Structure Therapeutics in the 2nd quarter valued at about $28,000. CWM LLC boosted its holdings in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the period. Assetmark Inc. grew its position in shares of Structure Therapeutics by 21.4% during the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after purchasing an additional 449 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $127,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of GPCR opened at $47.34 on Tuesday. The firm has a market capitalization of $3.30 billion, a PE ratio of -47.34 and a beta of -1.45. The company’s 50-day moving average is $50.68 and its 200-day moving average is $49.21. Structure Therapeutics has a fifty-two week low of $19.50 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Analysts predict that Structure Therapeutics will post -1.84 earnings per share for the current fiscal year.

About Structure Therapeutics

(Get Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.